Valuation: Norda ASA

Market Cap 513M 53.9M 48.15M 44.88M 40.69M 76.57M 5.12B 77.17M 538M 210M 2.66B 202M 198M 8.54B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.76M 24.8M 23.12M 20.96M 39.44M 2.64B 39.75M 277M 108M 1.37B 104M 102M 4.4B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-1.05%
Current month-1.05%
3 months-1.50%
Current year-14.90%
1 month 85.1
Extreme 85.1
86.4
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 2013-04-07
Director TitleAgeSince
Chairman 54 2014-01-30
Director/Board Member 68 2013-06-19
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%0.00%+5.06%+107.56% 45.87M
-0.32%-5.97%+57.78%+74.48% 70.44B
+2.31%-12.28%+7.04%+56.51% 50.31B
+3.46%+0.94%+11.31%+36.73% 47.51B
+1.05%+0.27%+27.93%+30.76% 42.91B
+0.55%-5.72%+286.54%+530.02% 40.39B
-0.65%-3.78%+6.74%+95.25% 39.69B
-0.39%-1.48%+10.41%+43.19% 30.59B
-2.95%-12.28%+43.51%+1.51% 26.8B
+1.06%-7.02%-12.99%-14.07% 22.36B
Average +0.27%-5.07%+44.33%+96.19% 37.1B
Weighted average by Cap. +0.59%-5.61%+51.73%+100.78%

Financials

2023 2024
Net sales 86.92M 9.13M 8.16M 7.6M 6.89M 12.97M 867M 13.07M 91.06M 35.65M 451M 34.29M 33.53M 1.45B 372M 39.05M 34.89M 32.52M 29.48M 55.48M 3.71B 55.92M 390M 152M 1.93B 147M 143M 6.19B
Net income 31.17M 3.27M 2.92M 2.73M 2.47M 4.65M 311M 4.69M 32.66M 12.78M 162M 12.3M 12.03M 519M 126M 13.23M 11.82M 11.01M 9.99M 18.79M 1.26B 18.94M 132M 51.65M 653M 49.68M 48.59M 2.1B
Net Debt -311M -32.69M -29.2M -27.22M -24.68M -46.44M -3.1B -46.8M -326M -128M -1.61B -123M -120M -5.18B -249M -26.13M -23.34M -21.76M -19.73M -37.13M -2.48B -37.42M -261M -102M -1.29B -98.14M -95.99M -4.14B
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock